Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence